Jul 13, 2024, 11:17
David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients
David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn:
“Great news, a new option in our 1st line strategy for NSCLC EGFRmut patients! To be discussed especially in our patients with brain metastases, ctDNA+ or high tumor load.”
Source: David Planchard/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14